Clinical Trial Closeup

Senolytic therapy: ‘Entirely new paradigm’

A look at UBX1325, a small-molecule B-cell inhibitor that targets the proteins senescent cells feed on for survival.

Sustained-release sunitinib comes to retina

A closer look at the extension study of GB-102 for treatment of neovascular age-related macular degeneration.

A potential stem-cell solution for GA

Trial shows safety of a biosynthetic patch inserted in a subretinal bleb in an outpatient procedure.

Targeting headwaters of classical pathway

The IgG antibody fragment ANX007 aims to disrupt the cascade that leads to geographic atrophy at the initiating molecule.

How THR-149 targets alternate pathway

The plasma kallikrein inhibitor is being investigated to treat diabetic macular edema that doesn’t respond to anti-VEGF therapy.

TKI vorolanib implant shows early signal

DAVIO Phase I results of EYP-1901 show reduced treatment burden in age-related macular degeneration.

Targeted approach to pan-VEGF inhibition

A suprachoroidal formulation of axitinib, approved for renal cell carcinoma, may have potential for treating neovascular AMD.

A potential disrupter of GA progression

A post-hoc analysis shows that pegcetacoplan may disrupt the complement pathway to potentially stabilize nascent or early atrophy.

PDS with ranibizumab: It’s in the technique

A closer look at Archway results and ‘a few important details’ for the implantation procedure that drives outcomes.

Targeting a key GA factor at its source

Investigational treatment FB-LRX targets complement factor B further up the complement cascade.